Thyroid Artery Embolization for the Treatment of Compressive Goiters.
Recruiting now NCT07360587
Run by Université de Sherbrooke · for 18 and older · All sexes
What this study is about
Very few studies have investigated TAE as a treatment for goiter with compressive symptoms. What is the efficacy and safety of TAE for the treatment of compressive goiters in a population ineligible for or refusing standard therapy? This is a prospective interventional cohort study that will allow us to standardize imaging by improving quality data collection and fellow-up to assess the efficacy of TAE for compressive symptoms of nodular goiters. Not only to corroborate current emerging results but clearly define the expected results for this technique.
Who can join (things the study team will check)
✅ You may be able to join if…
- Patient with compressive symptoms or significant tracheal or oesophageal compression at risk of causing symptoms attributed to a goiter AND
- Ineligible for surgery/ablative treatments or preference for TAE over other treatments AND
- TiRADS category 1, 2, 3 or 4 AND
- Bethesda categories I or III on 2 different biopsies OR Bethesda II on one biopsy AND
- Patient at least 18 years old.
🚫 You may not be able to join if…
- Comorbidities precluding endovascular procedure OR
- TiRADS category 5 OR
- Bethesda categories IV, V, VI on biopsy OR
- Refusal of the patient to participate OR
- Uncontrolled severe hyperthyroidism OR
- Minor patient.
Where this trial is running
- Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
Who to contact
Laurent Fradet, MD FRCSC · +1-819-346-1110 · Laurent.Fradet@USherbrooke.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07360587.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.